ERBB2 and neoplasm: To test whether the targeting and killing of tumors by immune responses were durable and expanded to antigen spread T cell responses, mice that rejected the CT26-HER-2 tumors were subsequently re-challenged with the parental CT26-WT tumor cell line that does not express HER-2 (Fig 7, red lines).